BR112019023846A2 - composição farmacêutica de anticorpo de pd-l1 e uso da mesma - Google Patents
composição farmacêutica de anticorpo de pd-l1 e uso da mesma Download PDFInfo
- Publication number
- BR112019023846A2 BR112019023846A2 BR112019023846A BR112019023846A BR112019023846A2 BR 112019023846 A2 BR112019023846 A2 BR 112019023846A2 BR 112019023846 A BR112019023846 A BR 112019023846A BR 112019023846 A BR112019023846 A BR 112019023846A BR 112019023846 A2 BR112019023846 A2 BR 112019023846A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- antibody
- provides
- present
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
a presente invenção provê uma composição farmacêutica de anticorpo de pd-l1 e uso da mesma. em particular, a presente invenção provê uma composição farmacêutica compreendendo o anticorpo de pd-l1 ou um fragmento de ligação ao antígeno do mesmo em um tampão de succinato. além disso, a composição farmacêutica também pode conter um açúcar e um tensoativo não iônico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710341680 | 2017-05-16 | ||
PCT/CN2018/086866 WO2018210230A1 (zh) | 2017-05-16 | 2018-05-15 | 一种pd-l1抗体药物组合物及其用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019023846A2 true BR112019023846A2 (pt) | 2020-06-09 |
Family
ID=64273337
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019023846A BR112019023846A2 (pt) | 2017-05-16 | 2018-05-15 | composição farmacêutica de anticorpo de pd-l1 e uso da mesma |
Country Status (13)
Country | Link |
---|---|
US (1) | US11654194B2 (pt) |
EP (1) | EP3626266A4 (pt) |
JP (1) | JP7263256B6 (pt) |
KR (1) | KR102623679B1 (pt) |
CN (1) | CN110198739B (pt) |
AU (1) | AU2018267843A1 (pt) |
BR (1) | BR112019023846A2 (pt) |
CA (1) | CA3062487A1 (pt) |
MX (1) | MX2019013751A (pt) |
MY (1) | MY195465A (pt) |
RU (1) | RU2766590C2 (pt) |
TW (1) | TWI734916B (pt) |
WO (1) | WO2018210230A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6983371B2 (ja) * | 2015-11-17 | 2021-12-17 | スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド | 抗pd−l1抗体、その抗原結合フラグメントおよびその医療用途 |
US20230287122A1 (en) * | 2018-11-29 | 2023-09-14 | Harbour Biomed Therapeutics Limited | Anti-pd-l1 antibody preparation |
CN113518823A (zh) * | 2019-01-07 | 2021-10-19 | 托马斯杰斐逊大学 | 多功能的融合蛋白及其用途 |
CN112125975B (zh) * | 2019-06-25 | 2024-03-01 | 上海翰森生物医药科技有限公司 | Pd-l1和cd47双特异性融合蛋白及其医药用途 |
EP3998081A4 (en) | 2019-07-05 | 2023-07-12 | Ono Pharmaceutical Co., Ltd. | TREATMENT OF BLOOD CANCER WITH PD-1/CD3 DUAL SPECIFICITY PROTEIN |
EP4011918A4 (en) | 2019-08-08 | 2023-08-23 | ONO Pharmaceutical Co., Ltd. | DUAL SPECIFIC PROTEIN |
CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
AR126614A1 (es) * | 2021-07-29 | 2023-10-25 | Shanghai Junshi Biosciences Co Ltd | Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma |
TW202333789A (zh) * | 2022-01-05 | 2023-09-01 | 大陸商上海邁晉生物醫藥科技有限公司 | 一種包含抗FXI/FXIa抗體的醫藥組成物及其用途 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9609743A (pt) | 1995-07-27 | 1999-03-02 | Genentech Inc | Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação |
ES2190087T3 (es) * | 1997-06-13 | 2003-07-16 | Genentech Inc | Formulacion estabilizada de un anticuerpo. |
ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
BRPI0613361A2 (pt) | 2005-07-01 | 2011-01-04 | Medarex Inc | anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1 |
KR20210060670A (ko) | 2008-12-09 | 2021-05-26 | 제넨테크, 인크. | 항-pd-l1 항체 및 t 세포 기능을 향상시키기 위한 그의 용도 |
BR122021025338B1 (pt) | 2009-11-24 | 2023-03-14 | Medimmune Limited | Anticorpo isolado ou fragmento de ligação do mesmo contra b7-h1, composição farmacêutica e seus usos |
KR102031020B1 (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
PE20160541A1 (es) * | 2013-09-27 | 2016-06-03 | Genentech Inc | Formulaciones de anticuerpos anti-pdl1 |
US10570202B2 (en) | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
CA2999079A1 (en) | 2015-09-28 | 2017-04-06 | Jiangsu Hengrui Medicine Co., Ltd. | Stable anti-pd-1 antibody pharmaceutical preparation and application thereof in medicine |
JP6983371B2 (ja) | 2015-11-17 | 2021-12-17 | スーヂョウ サンケイディア バイオファーマスーティカルズ カンパニー リミテッド | 抗pd−l1抗体、その抗原結合フラグメントおよびその医療用途 |
CN107198773A (zh) | 2017-06-08 | 2017-09-26 | 上海药明生物技术有限公司 | 重组抗pd‑l1全人单克隆抗体的液体制剂 |
-
2018
- 2018-05-15 RU RU2019139093A patent/RU2766590C2/ru active
- 2018-05-15 MX MX2019013751A patent/MX2019013751A/es unknown
- 2018-05-15 BR BR112019023846A patent/BR112019023846A2/pt unknown
- 2018-05-15 EP EP18801322.1A patent/EP3626266A4/en active Pending
- 2018-05-15 AU AU2018267843A patent/AU2018267843A1/en active Pending
- 2018-05-15 WO PCT/CN2018/086866 patent/WO2018210230A1/zh unknown
- 2018-05-15 CA CA3062487A patent/CA3062487A1/en active Pending
- 2018-05-15 JP JP2019563895A patent/JP7263256B6/ja active Active
- 2018-05-15 KR KR1020197036735A patent/KR102623679B1/ko active IP Right Grant
- 2018-05-15 CN CN201880007923.6A patent/CN110198739B/zh active Active
- 2018-05-15 US US16/614,148 patent/US11654194B2/en active Active
- 2018-05-15 MY MYPI2019006627A patent/MY195465A/en unknown
- 2018-05-16 TW TW107116620A patent/TWI734916B/zh active
Also Published As
Publication number | Publication date |
---|---|
KR102623679B1 (ko) | 2024-01-11 |
WO2018210230A8 (zh) | 2019-09-26 |
JP7263256B6 (ja) | 2023-07-24 |
US20200069800A1 (en) | 2020-03-05 |
RU2019139093A (ru) | 2021-06-16 |
CN110198739B (zh) | 2023-04-04 |
EP3626266A1 (en) | 2020-03-25 |
CN110198739A (zh) | 2019-09-03 |
WO2018210230A1 (zh) | 2018-11-22 |
JP2020520939A (ja) | 2020-07-16 |
CA3062487A1 (en) | 2018-11-22 |
RU2766590C2 (ru) | 2022-03-15 |
KR20200005650A (ko) | 2020-01-15 |
RU2019139093A3 (pt) | 2021-08-10 |
US11654194B2 (en) | 2023-05-23 |
TWI734916B (zh) | 2021-08-01 |
EP3626266A4 (en) | 2021-04-07 |
JP7263256B2 (ja) | 2023-04-24 |
AU2018267843A1 (en) | 2019-12-12 |
TW201900211A (zh) | 2019-01-01 |
MY195465A (en) | 2023-01-25 |
MX2019013751A (es) | 2020-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019023846A2 (pt) | composição farmacêutica de anticorpo de pd-l1 e uso da mesma | |
CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
CL2019003144A1 (es) | Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. | |
MX2020008219A (es) | Formulacion farmaceutica de ph bajo. | |
EP3476399A4 (en) | LAG-3 ANTIBODIES, ANTI-BINDING FRAGMENT THEREOF AND MEDICAL APPLICATION THEREOF | |
BR112017027778A2 (pt) | anticorpos para o fator xi e métodos de uso | |
WO2018222722A3 (en) | COMPOSITIONS COMPRISING ANTI-LAG-3 ANTIBODY OR ANTI-LAG-3 ANTIBODY AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY | |
AR080795A1 (es) | Anticuerpos anti-lrp6 (proteina relacionada con el receptor ldl tipo 6) | |
BR112016026811A2 (pt) | formulação de anticorpo | |
MA55868A (fr) | Anticorps monoclonal anti-ctla4 ou son fragment se liant à l'antigène, composition pharmaceutique et son utilisation | |
CY1124230T1 (el) | Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου | |
MX2018012651A (es) | Composiciones que comprenden coformulacion de anticuerpos anti-ligando-1 de muerte celular programada (pd-l1) y anti-antigeno-4 asociado a linfocitos t citotoxicos (ctla-4). | |
BR112017026704A2 (pt) | uso | |
BR112017003419A2 (pt) | formulação de anticorpo anti-il-4r-alfa estável | |
CU20200042A7 (es) | Formulación liofilizada de un anticuerpo monoclonal contra la transtirretina | |
PH12019501319A1 (en) | Gremlin-1 crystal structure and inhibitory antibody | |
EP4234013A3 (en) | Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3 | |
WO2020051333A8 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
EA201992027A1 (ru) | Водный состав антитела против pd-l1 | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
WO2018119351A8 (en) | Anti-sez6l2 antibodies and antibody drug conjugates | |
BR112018008977A2 (pt) | anti corpos humanizados anti-bag3 | |
MX2020009496A (es) | Metodo para tratar asma o enfermedad alergica. | |
BR112016029935A2 (pt) | ?anticorpos anti-brdu, complexo, formulação farmacêutica e uso de anticorpo? | |
EA202090627A1 (ru) | Способы оценки конъюгатов антитела и лекарственного препарата |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |